Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The specific skin disease variant p.(Arg2000Trp) in plectin can cause a wide range of symptoms, which should be considered when diagnosing patients.

The treatment was effective for advanced non-Hodgkin's lymphomas.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

SLE should be considered in horses with immune-related skin issues.

Effective vitiligo treatment requires targeting multiple biological factors, not just immune suppression.

Blocking certain proteins on immune cells may help treat alopecia areata.

Hepatitis B virus exposure may be linked to increased risk of alopecia areata.

Hair dye may trigger anti-GBM disease relapse, and rituximab can help manage it.

Low power red laser with efavirenz can reduce HIV-1 infection to undetectable levels and improve diagnosis.

Cell-based screening methods are useful and cost-effective for drug discovery but have pros and cons.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Certain proteins involved in DNA modification may affect the genetic changes in systemic lupus erythematosus and could indicate the disease's activity.

CK 15, follistatin, and Bmi-1 can help differentiate basal cell carcinoma from squamous cell carcinoma.

Mogamulizumab can cause hair loss and skin rashes.

Using Decamethoxine and Blastomunil together speeds up wound healing.

Abrocitinib may effectively treat stubborn alopecia universalis.

Men, diabetes, and high inflammation levels lead to higher COVID-19 antibodies.

Anti-Desmocollin 3 antibodies can cause pemphigus-like symptoms in mice.

Live vaccines can be safely given to infants with a FOXN1 variant if their immune function improves over time.

Autoimmune diseases with high tissue recovery often relapse and remit, while those with low recovery rarely remit.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

Patients with severe alopecia areata have higher levels of MIF, which decrease after successful treatment.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

A new image-based method improves accuracy in measuring hair loss in mice.

Unique microRNA patterns can help diagnose and treat severe alopecia areata.